Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Inovio Prices $80.5M Public Offering at $1.05 Per Share

Inovio Pharmaceuticals, Inc. filed a Form 8-K with the SEC on November 9, 2026, disclosing the pricing and terms of a public offering of common stock and pre-funded warrants expected to generate approximately $80.5 million in net proceeds.

Shwetambri Chauhan | 09 November 2026

Atea Pharmaceuticals Closes $200M Hercules Loan Facility

Atea Pharmaceuticals, Inc. filed a Current Report on Form 8-K on November 9, 2026, disclosing that it entered into a Loan and Security Agreement with Hercules Capital, Inc. on November 6, 2026, providing for term loans of up to $200.0 million.

Aditi Sarkar | 09 November 2026

Netcapital Gets Nasdaq Extension to File Overdue Reports

Netcapital Inc. filed a current report on November 9, 2026, disclosing that Nasdaq granted the company an exception period running through February 9, 2027, to file its overdue Annual Report and Quarterly Report after receiving delinquency notifications in August and September 2026.

Nitish Kishor | 09 November 2026

Ocular Therapeutix Elects Riad Sherif, M.D. to Board

Ocular Therapeutix, Inc. filed a current report on November 9, 2026, disclosing the election of Riad Sherif, M.D. to its Board of Directors effective November 6, 2026, and the forthcoming resignation of Seung Suh Hong, Ph.D., effective December 31, 2026.

Vinay Lochav | 09 November 2026

Goodyear Names Roger Wood Interim CEO, Stewart Departs

The Goodyear Tire & Rubber Company filed a Form 8-K on November 9, 2026, disclosing that Roger J. Wood was appointed Interim Chief Executive Officer and President effective November 8, 2026, replacing Mark W. Stewart, whose separation was classified as a termination "other than …

Vinay Lochav | 09 November 2026

Soluna Holdings Sets Q3 2026 Earnings Call for Nov. 16

Soluna Holdings, Inc. filed a Form 8-K on November 9, 2026, disclosing via Regulation FD that it will release its third quarter 2026 financial results on November 16, 2026, and host a conference call and webcast at 5:00 PM ET that day.

Aakashdeep | 09 November 2026

FACT II Acquisition Discloses Non-Redemption Agreements Before Nov. 17 Meeting

FACT II Acquisition Corp. filed a current report on November 9, 2026, disclosing plans to enter into non-redemption agreements with unaffiliated investors ahead of an extraordinary general meeting scheduled for November 17, 2026, to vote on extending the company's business combination deadline.

Aditi Sarkar | 09 November 2026

Immunovant Q2 FY2027: $250.5M Net Loss, $722M Cash

Immunovant, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a net loss of $250.470 million for the six months ended September 30, 2026, with cash and cash equivalents of $722.274 million as of that date.

Aditi Sarkar | 09 November 2026

Cullinan Velinotamig Phase 1b/2a SLE Data Disclosed

Cullinan Therapeutics, Inc. filed a current report on Form 8-K on November 9, 2026, disclosing interim clinical data from an ongoing Phase 1b/2a trial of velinotamig in patients with active, refractory, moderate-to-severe systemic lupus erythematosus, as presented at the American College of Rheumatology Convergence …

Nitish Kishor | 09 November 2026

Cadeler plc Initiates Squeeze-Out of Cadeler A/S Minority Shares

Cadeler plc filed a Form 6-K with the U.S. Securities and Exchange Commission on 9 November 2026, announcing the initiation of a compulsory acquisition of shares in Cadeler A/S held by remaining minority shareholders under sections 70 and 72 of the Danish Companies Act.

Manish Choudhary | 09 November 2026
Support

Hi! How can we help you today?

Loading…